Últimas noticias sobre RMR Gr (NASDAQ:RMR) Bolsa

RMR Gr

The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.

RMR Group

The RMR Group Inc. - Class A Common Stock

The RMR Group Inc

RADISSON MINING RESOURCES by Radisson Mining Resources Inc.

Radisson Mining Resources Inc

RAND MERCHANT INVT HLDG by Rand Merchant Invt Hldgs Ltd.

OUTsurance Group Ltd

RMR INDUSTRIALS CL B by RMR Industrials, Inc.

Rocky Mountain Industrials Inc

Rimrock Gold Corp

RMRK

Armory Mining Corp

<p>American Finl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) has outperformed the market over the past 20 years by 1.1% on an annualized basis producing an average annual return of 9.31%. Currently, American Finl Gr has a market capitalization of $10.16 billion. </p>
<p><strong>Buying $100 In AFG:</strong> If an investor had bought $100 of AFG stock 20 years ago, it would be worth <strong>$603.64</strong> today based on a price of $121.00 for AFG at the time of writing.</p>
<h3>American Finl Gr's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740514510_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

WIIM

HLIO

Helios Technologies shares are trading higher after the company reported better-than-expected Q4 revenue results and announced approval for a $100 million share repurchase program

GDS Holdings shares are trading lower after RBC Capital downgraded its rating on the stock from outperform to perform despite raising its price target from $26 to $37.

Helix Energy Solutions shares are trading higher after the company reported better-than-expected Q4 financial results.

UFPT

UFP Technologies shares are trading higher after the company reported better-than-expected Q4 financial results.

XMTR

Xometry shares are trading lower. The company reported Q4 financial results.

CMTG

Claros Mortgage Trust shares are trading lower after Wells Fargo and UBS cut their respective price targets on the stock.

Methode Electronics shares are trading higher after Sidoti & Co. upgraded the stock from Neutral to Buy and announced a price target of $14.

ADUS

Addus HomeCare shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

Obsidian Energy shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

AORT

Artivion shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and revenue estimates. Additionally, Needham and Stifel cut their respective price targets on the stock.

MYGN

Myriad Genetics shares are trading lower following a Q4 revenue miss and FY25 revenue guidance below estimates. The stock may also be trading on weakness after it announced it will face cost restructuring following UnitedHealthcare's decision to end Genesight coverage. Additionally, UBS and Raymond James cut their respective price targets on the stock.

<p>Financial giants have made a conspicuous bullish move on Starbucks. Our analysis of options history for Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) revealed 30 unusual trades.</p>
<p>Delving into the details, we found 53% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $659,935, and 16 were calls, valued at $732,423.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $145.0 for Starbucks during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Starbucks's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Starbucks's whale activity within a strike price range from $95.0 to $145.0 in the last 30 days. </p>
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513715_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$20.45</td>
<td>$20.35</td>
<td>$20.35</td>
<td>$100.00</td>
<td>$122.1K</td>
<td>0</td>
<td align="right">60</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$28.0</td>
<td>$26.4</td>
<td>$26.8</td>
<td>$135.00</td>
<td>$101.8K</td>
<td>0</td>
<td align="right">38</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$130.00</td>
<td>$95.4K</td>
<td>1.2K</td>
<td align="right">299</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$23.4</td>
<td>$23.05</td>
<td>$23.35</td>
<td>$130.00</td>
<td>$81.7K</td>
<td>71</td>
<td align="right">105</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$18.0</td>
<td>$15.35</td>
<td>$15.6</td>
<td>$115.00</td>
<td>$78.0K</td>
<td>1.0K</td>
<td align="right">54</td>
</tr>
</tbody>
</table>
</p>
<h3>About Starbucks</h3>
<p>Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries as of the end of fiscal 2024. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.</p>
<p>In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Starbucks</h3>
<ul>
<li>With a volume of 7,121,246, the price of SBUX is up 1.48% at $114.86. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 63 days.</li>
</ul>
<h3>What The Experts Say On Starbucks</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $114.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on Starbucks, maintaining a target price of $105.<br />
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Starbucks, targeting a price of $115.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $115.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Starbucks with a target price of $114.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Starbucks with a target price of $125. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

SBUX

A Closer Look at Starbucks's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Viking Therapeutics</strong>.</p>
<p>Looking at options history for Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 69% of the investors opened trades with bullish expectations and 30% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $453,915 and 7, calls, for a total amount of $500,554.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $100.0 for Viking Therapeutics over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $20.0 to $100.0 in the last 30 days. </p>
<h3>Viking Therapeutics Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513710_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$7.2</td>
<td>$35.00</td>
<td>$160.5K</td>
<td>1.3K</td>
<td>297</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.43</td>
<td>$1.42</td>
<td>$1.42</td>
<td>$25.00</td>
<td>$142.1K</td>
<td>216</td>
<td>1.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.85</td>
<td>$1.43</td>
<td>$1.44</td>
<td>$25.00</td>
<td>$141.6K</td>
<td>216</td>
<td>2.6K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.05</td>
<td>$0.99</td>
<td>$1.05</td>
<td>$35.00</td>
<td>$105.0K</td>
<td>6.0K</td>
<td>199</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.85</td>
<td>$1.46</td>
<td>$1.46</td>
<td>$25.00</td>
<td>$57.1K</td>
<td>216</td>
<td>2.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Viking Therapeutics</h3>
<p>Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.</p>
<p>Having examined the options trading patterns of Viking Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,281,250, the price of VKTX is down by -3.94%, reaching $28.05.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 57 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $81.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Maxim Group has decided to maintain their Buy rating on Viking Therapeutics, which currently sits at a price target of $70.<br />
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $38.<br />
&#x2A; An analyst from Raymond James has decided to maintain their Strong Buy rating on Viking Therapeutics, which currently sits at a price target of $125.<br />
&#x2A; An analyst from Scotiabank downgraded its action to Sector Outperform with a price target of $102.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Viking Therapeutics, maintaining a target price of $71. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


VKTX

A Closer Look at Viking Therapeutics's Options Market Dynamics

<p>Benzinga's options scanner has just identified more than 29 option transactions on Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), with a cumulative value of $2,093,239. Concurrently, our algorithms picked up 6 puts, worth a total of 589,741.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $61.0 for Roblox, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Roblox's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Roblox's substantial trades, within a strike price spectrum from $50.0 to $61.0 over the preceding 30 days.</p>
<h3>Roblox Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513705_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RBLX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.9</td>
<td>$2.82</td>
<td>$2.85</td>
<td>$60.00</td>
<td>$267.6K</td>
<td>7.7K</td>
<td>862</td>
</tr>
<tr>
<td>RBLX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.98</td>
<td>$2.9</td>
<td>$2.9</td>
<td>$60.00</td>
<td>$145.0K</td>
<td>7.7K</td>
<td>562</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.05</td>
<td>$8.9</td>
<td>$9.05</td>
<td>$60.00</td>
<td>$126.7K</td>
<td>3.9K</td>
<td>4.5K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.3</td>
<td>$9.25</td>
<td>$9.3</td>
<td>$60.00</td>
<td>$126.4K</td>
<td>3.9K</td>
<td>5.1K</td>
</tr>
<tr>
<td>RBLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.05</td>
<td>$9.0</td>
<td>$9.05</td>
<td>$60.00</td>
<td>$114.9K</td>
<td>3.9K</td>
<td>4.8K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Roblox</h3>
<p>Roblox operates a free-to-play online video game platform with about 85 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators—spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.</p>
<p>Following our analysis of the options activities associated with Roblox, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Roblox Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,091,008, the price of RBLX is down by -2.37%, reaching $59.62.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 72 days from now.</li>
</ul>
<h3>What The Experts Say On Roblox</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $69.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Outperform rating on Roblox with a target price of $76.<br />
&#x2A; Consistent in their evaluation, an analyst from Roth MKM keeps a Neutral rating on Roblox with a target price of $70.<br />
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Roblox, which currently sits at a price target of $72.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Roblox, which currently sits at a price target of $82.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Roblox, targeting a price of $46. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Roblox with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


RBLX

Decoding Roblox's Options Activity: What's the Big Picture?

<p>Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.25, with a high estimate of $36.00 and a low estimate of $31.00. A 0.75% drop is evident in the current average compared to the previous average price target of $33.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513705_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Anglogold Ashanti's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Patrick Jones</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Anglogold Ashanti. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Anglogold Ashanti compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Anglogold Ashanti's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Anglogold Ashanti's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Anglogold Ashanti analyst ratings.</strong></a></p>
<h2>Discovering Anglogold Ashanti: A Closer Look</h2>
<p>Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.</p>
<h3>Financial Milestones: Anglogold Ashanti's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Anglogold Ashanti's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>17.37%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Anglogold Ashanti's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>26.86%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Anglogold Ashanti's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>8.74%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.32%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Anglogold Ashanti's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.32</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

What 4 Analyst Ratings Have To Say About Anglogold Ashanti

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $77.67, a high estimate of $90.00, and a low estimate of $71.00. This current average represents a 6.79% decrease from the previous average price target of $83.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513697_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Trex Co's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Kurt Yinger</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rafe Jadrosich</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trex Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Trex Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Trex Co's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Trex Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TREX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Trex Co analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Trex Co</h2>
<p>Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.</p>
<h3>Breaking Down Trex Co's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Trex Co's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-23.08%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Trex Co's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>17.35%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Trex Co's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>4.55%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.2%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Trex Co's debt-to-equity ratio is below the industry average. With a ratio of <b>0.12</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TREX

What 6 Analyst Ratings Have To Say About Trex Co

<p>11 analysts have expressed a variety of opinions on Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $367.55, a high estimate of $407.00, and a low estimate of $316.00. This current average has increased by 2.13% from the previous average price target of $359.89. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513690_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Quanta Services's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$316.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$323.00</td>
<td>$388.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$350.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$371.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Drew Chamberlain</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$323.00</td>
<td>$297.00</td>
</tr>
<tr>
<td>Sherif El-Sabbahy</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$407.00</td>
<td>-</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$388.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$398.00</td>
<td>$399.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$399.00</td>
<td>$358.00</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$374.00</td>
<td>$343.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$394.00</td>
<td>$348.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Quanta Services. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Quanta Services compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Quanta Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quanta Services's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PWR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Quanta Services analyst ratings.</strong></a></p>
<h2>Discovering Quanta Services: A Closer Look</h2>
<p>Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric infrastructure and underground utility and infrastructure.</p>
<h3>Key Indicators: Quanta Services's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Quanta Services displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>13.3%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Quanta Services's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>4.66%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Quanta Services's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>4.24%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Quanta Services's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.63%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.61</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


11 Analysts Assess Quanta Services: What You Need To Know

<p>Across the recent three months, 5 analysts have shared their insights on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $115.6, with a high estimate of $126.00 and a low estimate of $105.00. This current average reflects an increase of 11.42% from the previous average price target of $103.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513670_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of HealthEquity's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on HealthEquity analyst ratings.</strong></a></p>
<h2>About HealthEquity</h2>
<p>HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.</p>
<h3>HealthEquity: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>20.55%</strong> as of 31 October, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>1.9%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> HealthEquity's ROE excels beyond industry benchmarks, reaching <strong>0.27%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> HealthEquity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.16%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.53</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About HealthEquity Stock

<p>16 analysts have expressed a variety of opinions on EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $54.44, a high estimate of $73.00, and a low estimate of $35.00. Surpassing the previous average price target of $50.43, the current average has increased by 7.95%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740513632_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of EQT's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$58.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Umang Choudhary</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>Bernstein</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$56.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$49.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to EQT. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of EQT compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for EQT's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of EQT's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on EQT analyst ratings.</strong></a></p>
<h2>Get to Know EQT Better</h2>
<p>EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and the transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.</p>
<h3>Financial Milestones: EQT's Journey</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, EQT showcased positive performance, achieving a revenue growth rate of <strong>31.87%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> EQT's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.14%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> EQT's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.04%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.05%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> EQT's debt-to-equity ratio is below the industry average. With a ratio of <b>0.45</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


16 Analysts Assess EQT: What You Need To Know

Press Releases

Diversified Healthcare Trust Fourth Quarter 2024 Conference Call Scheduled for Wednesday, February 26th

Service Properties Trust Fourth Quarter 2024 Conference Call Scheduled for Thursday, February 27th

Diversified Healthcare Trust Completes $159.0 Million Sale of MUSE Life Science Asset in San Diego, California

The RMR Group Inc. Announces First Quarter Fiscal 2025 Results

Office Properties Income Trust Announces Private Exchange Offers Relating to Existing 2026, 2027 and 2031 Senior Unsecured Notes

Office Properties Income Trust Announces Fourth Quarter 2024 Results

Office Properties Income Trust Issues Supplement to Previously Announced Private Exchange Offers Relating to Existing Senior Unsecured Notes to Reflect Certain Financial Information in its 10-K Filed Earlier Today

Seven Hills Realty Trust Announces Fourth Quarter 2024 Results

Industrial Logistics Properties Trust Announces Fourth Quarter 2024 Results

Office Properties Income Trust Announces Extension of the Early Delivery Time and Withdrawal Deadline for Previously Announced Private Exchange Offers Relating to Existing Senior Unsecured Notes

Comments

RMR Gr

Noticias

Últimas noticias sobre RMR Gr (NASDAQ:RMR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL